

Precision Medicine Testing Recommendations For: Hepatocellular Carcinoma

Who should be tested?

- Treatment eligible
- Metastatic disease

When and what should be tested?

- At time of initial diagnosis
- Recurrence
- Tissue or liquid

What tests should be considered?

- NCCN/FDA APproved
 - dMMR/MSI-H
 - NTRK *
- Emerging Biomarkers
 - IDH1
 - IDH2
 - FGF
 - KRAS
 - Expanded NGS panel
- Informational considerations:
 - FGF

*Ensure inclusion into the molecularly targeting set of testing recommendatios